Related Experiment Videos
Sodium valproate in schizophrenia: some biochemical correlates
The British Journal of Psychiatry : the Journal of Mental Science
|September 1, 1980
Summary
Sodium valproate, an epilepsy drug, worsened symptoms in five of eight schizophrenia patients. Cerebrospinal fluid analysis revealed no significant changes in key neurotransmitters, but homovanillic acid showed a slight increase.
Area of Science:
- Neuroscience
- Psychopharmacology
- Clinical Psychiatry
Background:
- Schizophrenia is a complex psychiatric disorder.
- Current treatments for schizophrenia have limitations.
- Valproate is an anticonvulsant medication with mood-stabilizing properties.
Purpose of the Study:
- To investigate the effects of sodium valproate on schizophrenic patients.
- To assess changes in cerebrospinal fluid (CSF) neurotransmitters during valproate treatment.
Main Methods:
- Eight patients diagnosed with schizophrenia received sodium valproate at daily doses ranging from 750 to 3000 mg.
- Cerebrospinal fluid (CSF) samples were analyzed for levels of gamma-amino-butyric acid (GABA), methoxy hydroxyphenyl glycol (MHPG), and homovanillic acid (HVA).
Main Results:
- Five out of eight patients experienced a qualitative increase in schizophrenic symptoms while on sodium valproate.
- No significant changes were observed in CSF GABA or MHPG levels.
- A non-significant increase in CSF homovanillic acid (HVA) was noted in five patients.
Conclusions:
- Sodium valproate may exacerbate symptoms in some individuals with schizophrenia.
- The observed changes in HVA suggest a potential, albeit non-significant, impact on dopamine metabolism.
- Further research is warranted to understand the neurobiological mechanisms and clinical implications of valproate in schizophrenia.